Adam Feuerstein, a noted biotech reporter for STAT News, highlighted earlier a tweet thread from Twitter account “Midwestern Hedgie,” who acknowledges being short “a little bit” of shares of Veru previously and to having “added aggressively today to our short position.” The stock was higher in the pre-market and extending into this morning after Jefferies predicted that yesterday morning’s COVID-19 data would lead to an Emergency Use Authorization, or EUA, for Veru by the FDA in 30 days. In his tweets laying out a short thesis on Veru, “Midwestern Hedgie” stated in part: “17% of the patients in the sabizabulin group died, and 35% of the patients in the placebo group died. It’s EXACTLY what you’d expect if deaths were being caused by Covid + hypoxemia (which they are), and sabizabulin was doing absolutely nothing… IMO (as an M.D. who taught evidence-based medicine to colleagues & residents) this drug has zero chance of an EUA.” In late morning trading, Veru shares remain up $1.06, or 8%, to $14.08, though off their earlier highs.
previous post